Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool February 4, 2008 Brian Lawler	Disenchanted With Chantix The FDA issues a health advisory for Chantix, Pfizer's new non-nicotine stop-smoking treatment.
The Motley Fool November 17, 2009 Brian Orelli	This Partnership Is Smoking! Glaxo and Nabi team up for smokers who want to quit. Let's just hope they don't flame out in phase 3 trials.
The Motley Fool March 19, 2007 Michael P. Cecil	Pfizer's Newest Blockbuster? Will Chantix help Pfizer cure its ailing stock price?
The Motley Fool July 11, 2008 Brian Orelli	Pfizer Looking at a Level Playing Field An advisory panel says that epilepsy drugs don't need a black-box warning, news that is positive for drug companies -- that is, those other than Pfizer.
BusinessWeek November 29, 2004 Carey & Barrett	Lessons From The Vioxx Fiasco What drugmakers, the FDA, doctors, and patients need to do.
The Motley Fool November 8, 2004 Brian Gorman	Pfizer's Gloom Factor The stock will continue to be depressed, but things will improve if Celebrex's safety is proven.
The Motley Fool June 6, 2011 Brian Orelli	Big Pharma Tackles Lung Cancer; Biotech Helping, Too A big underserved market.
The Motley Fool September 8, 2008 Brian Orelli	Another FDA Safety Warning (Yawn) The FDA warning results from numerous reports of fungal infections in patients taking TNF inhibitors.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
The Motley Fool February 23, 2005 Stephen D. Simpson	Take Two on COX-2 FDA panel recommendations breathe new life into Merck and Pfizer's COX-2 pain medications. Looking ahead, investors should give a good, long look to the drug sector.
American Family Physician April 1, 2001	Preventing Heart Attacks: What Women Need to Know Heart disease is the leading cause of death in women in the United States. American women are four to six times more likely to die of heart disease than of breast cancer. Here are some ways you can lower your risk of having a heart attack...
The Motley Fool March 13, 2009 Brian Orelli	Pfizer Finally Gets a Hit! Positive results on Pfizer's cancer drug Sutent come earlier than expected.
The Motley Fool October 9, 2008 Brian Orelli	When Science, Marketing, and Investing Collide How a pharmaceutical tries to sell more drugs can provide clues about its management.
The Motley Fool March 25, 2011 Brian Orelli	Pfile Pfizer Under "Potential" Researchers reported promising finding from a clinical trial of Pfizer's new drug, CP-870,893, in pancreatic cancer patients in the most recent issue of the journal Science.
AskMen.com	WHO: Get Graphic With Smokers Cigarette packages should include images of sickness and suffering caused by tobacco, along with written warnings, the World Health Organization said.
The Motley Fool February 24, 2011 Brian Orelli	Profit From Personalized Medicine Pfizer's drug works well, but consider these companies instead.
The Motley Fool January 22, 2010 Brian Orelli	Pfizer's Great Data Won't Do Much The full data from a clinical trial testing Pfizer's Sutent in pancreatic cancer was truly amazing. Unfortunately, it's not going to do very much for the stock or Pfizer's bottom line.
The Motley Fool November 13, 2009 Brian Orelli	Questioning Pfizer's Integrity Pfizer's epilepsy drug Neurontin has had generic competition for a few years, but it's still plaguing the pharmaceutical giant.
AskMen.com March 16, 2003 Mike Davison	Light Smokers Still Run Cancer Risk Significantly reducing the number of cigarettes you smoke a day may not be as helpful or as healthy as once thought.
The Motley Fool November 23, 2009 Brian Orelli	The Side Effect of Developing Obesity Drugs The FDA is fickle when it comes to weight-loss drugs.
American Family Physician September 15, 2000	Using Tobacco: Why You Need to Quit Why do I need to stop using tobacco?... Why is it so hard to stop smoking?... How can I stop smoking?... How do I get ready to stop smoking?... What will happen when I stop smoking?... What is nicotine replacement?... What is bupropion (Zyban)?...
The Motley Fool December 6, 2011 Brian Orelli	Pfizer Faces Firing Line A panel of outside experts will help decide Inlyta's fate.
The Motley Fool August 29, 2011 Brian Orelli	Drug Approved for Few Patients -- but That's OK The age of personalized medicine is upon us. Earlier this month, the FDA approved Roche's melanoma drug Zelboraf for patients with a specific mutation in BRAF. And on Friday, the agency approved Pfizer's Xalkori for lung cancer patients that are ALK-positive.
The Motley Fool June 3, 2011 Brian Orelli	FDA Bullies Obesity Drugmakers It's been clear for some time that the Food and Drug Administration isn't particularly fond of obesity drugs. Now it's just being a bully.
Salon.com June 15, 2001 Elizabeth M. Whelan	Tobacklash! One man wins $3 billion from Philip Morris and suddenly people are pro-big tobacco. What have they been smoking?
The Motley Fool August 28, 2009 Brian Orelli	Abbott Signs Up Another One Abbott announces that it has set up a partnership with Pfizer to run tests on Pfizer's new drug.
The Motley Fool July 30, 2007 Brian Orelli	Glaxo Puffs Up Targacept In the weird world of drug partnerships, GlaxoSmithKline, maker of antismoking nicotine patches, is teaming up with Targacept to investigate the positive effects of nicotine. Investors, take note.
The Motley Fool November 21, 2008 Brian Orelli	Viagra Stays Behind the Counter All puns about soft sales and wishing something would go up in this market have been removed from this article.
The Motley Fool September 8, 2008 Rich Duprey	The Coming Great Pharma Panic The FDA's drug warning list provides dangerously little information.
Nurse Practitioner April 2012 Chaney & Sheriff	Evidence-based treatments for smoking cessation Smoking addiction is both physical and mental. The etiology of tobacco dependence is multidimensional and includes physiological, psychological, and social/behavioral factors.
American Family Physician November 1, 2002	Heart Disease and Smoking: Why You Need to Stop Smoking Why do I need to stop smoking?... Why is it so hard to stop smoking?... What about nicotine replacement products or medicine to help me stop smoking?... How do I get support and encouragement?
Chemistry World July 12, 2012	Drawing on drugs to kick the habit While pharma companies stand accused of giving up on drugs to help people stop smoking, tobacco firms are looking at controversial nicotine replacement products. Anthony King surveys an area that is problematic on all sides.
The Motley Fool December 17, 2004 W.D. Crotty	Painful Pain Drugs Pfizer joins Merck in the COX-2 inhibitor penalty box. Pfizer's stock, has drifted down since the Vioxx news.
Chemistry World July 2007 Lisa Melton	There's More to Quitting Than Nicotine As England joins the growing list of nations to ban smoking in enclosed public places, this article explores the medicinal arsenal that could help to kick the habit
The Motley Fool September 16, 2008 Brian Lawler	Pfizer Puts Safety First Increased FDA scrutiny may motivate the pharmaceutical's new drug-safety site.
American Family Physician July 15, 2006 Okuyemi et al.	Interventions to Facilitate Smoking Cessation Family physicians, who see many tobacco addicted patients in their offices every year, have an important opportunity to decrease smoking rates with office-based interventions.
The Motley Fool November 10, 2009 Colleen Paulson	Altria's Not Tobacco's Only Altruist Reynolds American may purchase a quit-smoking company.
Pharmaceutical Executive May 1, 2006 Ron Feemster	Teamsters v. Pfizer A New Jersey Teamsters local says Pfizer tricked them into paying for off-label Lipitor prescriptions. Do you have any questions about that? We do.
The Motley Fool March 31, 2011 Brian Orelli	Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good.
The Motley Fool August 23, 2004 Ben McClure	Rethinking Big Pharma Risk is knocking Big Pharma stocks down. They won't be getting up anytime soon. Competition, soaring R&D costs, shifting business models, and political meddling combine to make drug stocks a riskier place to invest.
The Motley Fool January 8, 2010 Brian Orelli	Pfizer's Having a Garage Sale Rather than sending its unwanted drugs to the trash bin, the giant drugmaker is striking deals with its comrades to take them off its hands.
The Motley Fool June 6, 2008 Brian Lawler	Sorry, Sanofi: More Bad News The pharmaceutical's top drug prospect is linked to more side effects.
The Motley Fool April 21, 2008 Brian Lawler	Pfizer Is Still Floundering Generic competition keeps pounding away at its sales and profits.
The Motley Fool February 22, 2008 Selena Maranjian	Smoking Around the World What if hundreds of millions of people around the world quit smoking?
Seasoned Cooking July 2004 Michael Fick	Women's Heart Health: Part Two Ladies, heart attacks are your primary killer, yet 82% of your heart disease is self-induced by bad habits, and thus avoidable.
American Family Physician March 15, 2005 Lockman et al.	Treatment of Cholesterol Abnormalities The relationship between coronary heart disease and elevated cholesterol levels has been recognized for many years, but now studies show an improvement in patient-oriented outcomes in patients receiving drug therapy.
American Family Physician August 1, 2000	Do I Want to Quit Smoking? Questionaire about quitting smoking and what you can do about nicotine withdrawal
The Motley Fool July 18, 2011 Jim Royal	Big Tobacco Faces Another Huge Headwind More packaging changes could dent these players' profits.
The Motley Fool December 21, 2004 Brian Gorman	Pfizer Won't Let Go Pfizer is hoping that Celebrex will survive in some form. But the pharmaceutical giant has also determined that the drug should no longer be advertised to consumers. Its shares were pounded again following its revelation that it would pull such ads.
BusinessWeek February 28, 2005 Amy Barrett	Pfizer's Funk Pfizer CEO Hank McKinnell helped pioneer the age of blockbuster drugs. The company now spends twice as much on sales and administrative expenses as it does on R&D. But a dearth of new products and fears over drug safety are hurting the entire industry. Is there a fix?